All In Biotech

Drug Trial Radar · NCT00680732

Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component

Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso: the Malaria Component

Last checked: Nov 19, 2026Latest source record: Sep 14, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,370 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,370

Actual

Start

Jun 2003

Primary completion

Oct 2006

Study completion Oct 2006

Sponsor

Lead sponsor
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Departments of Parasitology and Public Health, ITM, Antwerp, Belgium; Centre Muraz; Laboratoire National de Santé Publique, Ouagadougou, Burkina Faso
First posted
May 20, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 15 years, up to 44 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Our objective was to investigate the importance of malaria infection/disease during pregnancy and more particularly during the first trimester; we also looked at the maternal-foetal interactions and their influence on the subsequent child's response to malaria infections during the first year of life. This study was carried out !in the same population recruited for the IUGR study (NCT00642408).

Conditions

  • Malaria
  • Malaria in Pregnancy

Interventions

  • Multiple micronutrients supplements (MMS)Dietary supplement

    Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg

  • Iron and folic acid (IFA)Dietary supplement

    Iron 60 mg and folic acid 400 mcg

  • Chloroquine (CQ)Drug

    Tablets 100 mg of chloroquine base

  • Sulphadoxyne-pyrimethamine (SP)Drug

    Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of standard antimalarial treatment in preventing clinical malaria in pregnant women under weekly chemoprophylaxis or intermittent treatment.Time frame: Up to delivery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre Muraz

    Bobo-Dioulasso, Burkina Faso

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.